For research use only. Not for therapeutic Use.
Safinamide(CAT: I001294) is a selective and reversible inhibitor of monoamine oxidase B (MAO-B). MAO-B is an enzyme that breaks down dopamine in the brain. By inhibiting MAO-B, safinamide increases dopamine levels, which can help improve symptoms of Parkinson’s disease. Safinamide is used as an adjunctive treatment for Parkinson’s disease to help control motor symptoms and fluctuations in response to levodopa therapy. Additionally, safinamide has also shown potential neuroprotective effects, which may contribute to its therapeutic benefits in Parkinson’s disease.
| Catalog Number | I001294 |
| CAS Number | 133865-89-1 |
| Synonyms | (2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide |
| Molecular Formula | C17H19FN2O2 |
| Purity | ≥95% |
| Target | Calcium Channel |
| Solubility | 10 mM in DMSO |
| Storage | Store at -20°C |
| IC50 | 98 nM [1] |
| Reference | </br>1:Safinamide for the treatment of Parkinson/’s disease. Scott RM, Schapira A.Expert Opin Pharmacother. 2017 May 15. doi: 10.1080/14656566.2017.1329819. [Epub ahead of print] PMID: 28504022 </br>2:Identification, Characterization, and Quantification of Impurities of Safinamide Mesilate: Process-Related Impurities and Degradation Products. Zou L, Sun L, Zhang H, Hui W, Zou Q, Zhu Z.J AOAC Int. 2017 Feb 2. doi: 10.5740/jaoacint.16-0218. [Epub ahead of print] PMID: 28150570 </br>3:Safinamide: A Review in Parkinson/’s Disease. Blair HA, Dhillon S.CNS Drugs. 2017 Feb;31(2):169-176. doi: 10.1007/s40263-017-0408-1. PMID: 28110399 </br>4:Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. Schapira AH, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, Kulisevsky J, Pahwa R, Poewe W, Anand R.JAMA Neurol. 2017 Feb 1;74(2):216-224. doi: 10.1001/jamaneurol.2016.4467. PMID: 27942720 </br>5:Effects of Safinamide on Pain in Fluctuating Parkinson/’s Disease Patients: A Post-Hoc Analysis. Cattaneo C, Barone P, Bonizzoni E, Sardina M.J Parkinsons Dis. 2017;7(1):95-101. doi: 10.3233/JPD-160911. PMID: 27802242 Free PMC Article</br>6:Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson/’s disease. Loprete L, Leuratti C, Cattaneo C, Thapar MM, Farrell C, Sardina M.Pharmacol Res Perspect. 2016 Aug 8;4(5):e00251. eCollection 2016 Oct. PMID: 27713822 Free PMC Article</br>7:Clinical Pharmacokinetics and Pharmacodynamics of Safinamide. Müller T, Foley P.Clin Pharmacokinet. 2017 Mar;56(3):251-261. doi: 10.1007/s40262-016-0449-5. Review. PMID: 27665574 </br>8:Emerging approaches in Parkinson/’s disease – adjunctive role of safinamide. Müller T.Ther Clin Risk Manag. 2016 Aug 2;12:1151-60. doi: 10.2147/TCRM.S86393. eCollection 2016. Review. PMID: 27536120 Free PMC Article</br>9:Adjuvant therapies for Parkinson/’s disease: critical evaluation of safinamide. Stocchi F, Torti M.Drug Des Devel Ther. 2016 Feb 5;10:609-18. doi: 10.2147/DDDT.S77749. eCollection 2016. Review. PMID: 26917951 Free PMC Article</br>10:Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson/’s Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE. Cattaneo C, Sardina M, Bonizzoni E.J Parkinsons Dis. 2016;6(1):165-73. doi: 10.3233/JPD-150700. PMID: 26889632 Free PMC Article |
